Bolar and Vitarine sued again
Generic firms sued in class action filed in Pennsylvania federal court by SmithKline Beecham shareholders, Bolar disclosed June 27. Complaint alleges violations of racketeering and federal securities statutes "in connection with allegations that Bolar and Vitarine submitted false or misleading information to FDA in gaining approval" of generic versions of Dyazide, Bolar notes. Smith-Kline Beecham also filed a complaint against the two firms and Schein alleging unfair competition ("The Pink Sheet" June 18, T&G-8).
You may also be interested in...
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.